Vicadrostat not checked
Boehringer Ingelheim · BI 690517
FollowEvery change as it happens, and a Monday email
Trials
5 active
18 in total · 10 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Heart Failure (2 trials), Kidney Disease, Chronic, Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Main trialPhase 3
- “This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with…”In the company’s words, NCT06531824 on ClinicalTrials.gov
- Other names
- BI 690517
Other drugs for Heart Failure
- Balcinrenone/ dapagliflozinAstraZeneca · Phase 3
- DapagliflozinAstraZeneca · Phase 3
- HiCM-188HELP Therapeutics Co., Ltd. · Phase 3
- Omecamtiv MecarbilCytokinetics · Phase 3
- InclisiranNovartis Pharmaceuticals · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
Coming up5
- 11 DecPhase 1 trial completes · ClinicalTrials.gov
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
- 22 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 4 Feb 2029Phase 3 trial completes · ClinicalTrials.gov
- 14 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials18
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Dec 2026 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | |
| Phase 3Recruiting | 22 May 2028 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | |
| Phase 3Recruiting | 4 Feb 2029 | A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | |
| Phase 3Recruiting | 14 Dec 2029 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | |
| Phase 1Recruiting | 11 Dec 2026 | A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body | |
| Phase 2Completed | 19 Jun 2023 | A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease | |
| Phase 2Completed | 14 Aug 2026 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease | |
| Phase 1Completed | 12 Dec 2016 | Single Rising Dose Study of BI 690517 in Healthy Volunteers | |
| Phase 1Completed | 13 Oct 2017 | This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated | |
| Phase 1Completed | 24 Nov 2017 | This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood | |
| Phase 1Completed | 31 Jan 2019 | A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are Tolerated | |
| Phase 1Completed | 16 Apr 2020 | This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated | |
| Phase 1Completed | 17 Nov 2022 | A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body | |
| Phase 1Completed | 13 Apr 2023 | A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems | |
| Phase 1Completed | 12 Dec 2024 | A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood | |
| Phase 1Completed | 7 Aug 2025 | A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together | |
| Phase 1Completed | 22 Oct 2025 | A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood | |
| Phase 1Completed | 24 Jul 2026 | A Study in Healthy People to Test How Vicadrostat Affects the Heart |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026